Entinostat, nivolumab and ipilimumab in advanced HER2-negative breast cancer

Novel Combo Promising in Advanced HER2-Negative Breast Cancer - Medpage TodayПодробнее

Expert report on treatment with Tumour-Infiltrating Lymphocytes (TILs)Подробнее

Entinostat addition fails to improve AI-resistant breast cancer outcomes | Roisin ConnollyПодробнее

Metastatic HER2 Negative Breast Cancer: Emerging Novel Treatment StrategiesПодробнее

Combining epigenetic modulators and immune checkpoint blockade in cancerПодробнее

GS2-10: "Nimbus: A phase 2 trial of nivolumab plus ipilimumab for patients with hypermutated..."Подробнее

Nivolumab and ipilimumab with tumour-infiltrating lymphocytes to treat triple-negative breast ca...Подробнее

ICON: chemotherapy combined with ipilimumab and nivolumab in metastatic HR+ breast cancerПодробнее

CheckMate-8HW: nivolumab and ipilimumab in MSI-H/dMMR mCRCПодробнее

Impact of CDK4/6 inhibitors on HR-positive, HER2-negative advanced breast cancerПодробнее

POLARIS: palbociclib for BIPOC patients with HER2-negative breast cancerПодробнее

Did you know that HER2-positive breast cancer accounts for up to 15-20% of all breast cancers?Подробнее

Get to know HER2-positive breast cancer and its targeted treatmentsПодробнее

Expert Report on advances in the management of HER2-negative and HER2-low advanced breast cancerПодробнее

The FINER Clinical Trial AnimationПодробнее

Unlocking the secrets of HER2+ve breast cancerПодробнее

New and emerging agents in HER2-negative metastatic breast cancer: Implications for practiceПодробнее

Mafalda Oliveira, SABCS 2022: Camizestrant vs fulvestrant for advanced ER+ HER2- breast cancerПодробнее

Personalized treatment of advanced HER2-negative gastric or gastroesophageal junction cancerПодробнее